Citigroup
LABU icon

Citigroup’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Citigroup’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,785
Closed -$13.6M – 6895
2020
Q4 		$13.6M Sell
6,785
-1,950
-22% -$3.11M 0.01% 1313
2020
Q3 		$9.36M Sell
8,735
-1,550
-15% -$1.78M 0.01% 1417
2020
Q2 		$12.2M Sell
10,285
-3,505
-25% -$3.04M 0.01% 1161
2020
Q1 		$6.22M Buy
13,790
+2,855
+26% +$2.6M 0.01% 1495
2019
Q4 		$12.6M Buy
10,935
+4,390
+67% +$3.94M 0.01% 1290
2019
Q3 		$4.04M Buy
6,545
+685
+12% +$569K ﹤0.01% 2136
2019
Q2 		$5.88M Buy
5,860
+2,795
+91% +$2.71M ﹤0.01% 1837
2019
Q1 		$3.67M Buy
3,065
+215
+8% +$224K ﹤0.01% 2057
2018
Q4 		$1.87M Buy
2,850
+2,050
+256% +$2.15M ﹤0.01% 2740
2018
Q3 		$1.49M Buy
800
+265
+50% +$521K ﹤0.01% 3051
2018
Q2 		$1.02M Sell
535
-640
-54% -$1.13M ﹤0.01% 3346
2018
Q1 		$1.87M Buy
1,175
+835
+246% +$1.55M ﹤0.01% 2655
2017
Q4 		$529K Buy
340
+315
+1,260% +$482K ﹤0.01% 4039
2017
Q3 		$43K Buy
+25
New +$34.7K ﹤0.01% 6058

Other funds holding LABU

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return
Belvedere Trading
Belvedere Trading Chicago, Illinois $84.4B AUM 52.68% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Citigroup's LABU Position: Q1 2026 in Review

Citigroup sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q1 2026, closing a stake of 1 share — an estimated $159 sold.

Citigroup first reported a position in LABU in Q2 2015 and held it in 32 quarters. The position peaked at $12.8M in Q3 2017. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2026.

  • Citigroup reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1 Direxion Daily S&P Biotech Bull 3X ETF share in Q1 2026, an estimated $159.
  • Citigroup first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q2 2015 and held it in 32 quarters.
  • Citigroup's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $12.8M in Q3 2017.
  • 33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.